-transparent.png){kind=logo}
OBJECTIVE Impairment of linear growth is a common clinical feature in patients with beta-thalassaemia major. Although growth hormone secretion appears to be normal in many short thalassaemic patients, it proves to be deficient in some of them. In these cases, administration of biosynthetic growth hormone seems justified. The aim of this study was to evaluate the effect of such treatment in a group of patients with beta-thalassaemia major presenting with growth failure and impairment of growth hormone secretion. METHODS Recombinant human growth hormone, 0.6 U/kg body weight per week, given subcutaneously in three divided doses, was administered for 12 months. METHODS Eight prepubertal patients with beta-thalassaemia major, presenting with severe growth retardation and impaired growth hormone secretion in response to provocative stimuli (insulin-induced hypoglycaemia, L-dopa and growth hormone-releasing hormone), were investigated. METHODS Height and pubertal stage of the patients, as well as plasma levels of insulin-like growth factor I, were determined before, during and after biosynthetic growth hormone treatment. RESULTS During the first 6 months of therapy, a significant increase of growth velocity was observed, from a mean pretreatment value of 2.1 +/- 0.45 cm/year to a value of 4.8 +/- 0.66 cm/year (P less than 0.002). Mean growth rate at 12 months (4.1 +/- 0.50 cm/year), though slightly decreased in comparison to that recorded at 6 months, was still significantly higher than basal (P less than 0.001). A significant increase in plasma levels of insulin-like growth factor I was recorded during treatment (2.82 +/- 0.47 vs 0.96 +/- 0.22 U/ml, P less than 0.005). No side-effects, adverse reactions or alterations in routine laboratory examinations ensued during or after therapy. CONCLUSIONS It appears from these data that biosynthetic growth hormone administration is worth serious consideration in patients with beta-thalassaemia major presenting growth retardation and impaired growth hormone secretion.
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
November 1992,
European journal of pediatrics,
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
March 2010,
Archives of medical science : AMS,
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
January 1994,
Minerva pediatrica,
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
September 2008,
The Journal of clinical endocrinology and metabolism,
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
December 2014,
Likars'ka sprava,
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
January 2020,
Saudi medical journal,
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
July 1992,
Acta endocrinologica,
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
January 1996,
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
May 1992,
The Journal of pediatrics,
M Scacchi, and
L Danesi, and
M De Martin, and
A Dubini, and
L Forni, and
A Masala, and
D Gallisai, and
C Burrai, and
S Terzoli, and
C Boffa
January 1998,
Journal of pediatric endocrinology & metabolism : JPEM,
